MedTrace Logo

Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program

NCT02024204 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-02-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to understand why patients in the World Trade Center program have continuing breathing problems. This study will improve investigators understanding of breathing problems among individuals with World Trade Center exposure by allowing them to review and monitor medication use, lung function, and examine other conditions that can contribute to problems with breathing. The findings from the study will help investigators understand why some people have persistent lower respiratory symptoms (breathing problems) after their exposure to World Trade Center dust and fumes, and may help guide better management and treatment of these symptoms.

Conditions

  • Lung Diseases
  • Medication Compliance

Interventions

DRUG

Fluticasone propionate 230mcg for 3 Months

DRUG

Current Treatment or no treatment

Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.

DRUG

Salmeterol 21mcg for 3 Months

Sponsors & Collaborators

  • National Institute for Occupational Safety and Health (NIOSH/CDC)

    collaborator FED

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Joan Reibman, M.D · NYU School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-09
Primary Completion
2017-05-17
Completion
2017-05-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02024204 on ClinicalTrials.gov